Hermann, M; Ruschitzka, F (2007). Cardiovascular risk of cyclooxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs. Annals of Medicine, 39(1):18-27.
Full text not available from this repository.
Since selective cyclooxygenase-2 inhibitors (coxibs) entered the market, there has been concern about the cardiovascular safety of coxibs. In addition, recent data suggest that classical non-steroidal anti-inflammatory drugs (NSAIDs) have a similar cardiovascular risk. Importantly, all of the clinical trials with NSAIDs and coxibs so far were not purpose-designed to specifically and prospectively address cardiovascular safety and were clearly underpowered to detect any meaningful differences. In this current uncertainty about safety of NSAIDs and coxibs, the definitive answer as to the net effect of coxibs and NSAIDs on cardiovascular events can only be provided by well designed adequately powered, long-term clinical trials, which is now under way
|Item Type:||Journal Article, refereed, further contribution|
|Communities & Collections:||04 Faculty of Medicine > University Hospital Zurich > Clinic for Cardiology|
|DDC:||610 Medicine & health|
|Uncontrolled Keywords:||Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/therapeutic use;Cardiovascular Diseases/*chemically induced;Clinical Trials as Topic;Cyclooxygenase 2 Inhibitors/*adverse effects/therapeutic use;Humans;Pain/*drug therapy;Prognosis;Risk Factors|
|Deposited On:||04 Jan 2011 15:36|
|Last Modified:||27 Nov 2013 18:28|
|Free access at:||PubMed ID. An embargo period may apply.|
|Citations:||Web of Science®. Times Cited: 20|
Scopus®. Citation Count: 24
Users (please log in): suggest update or correction for this item
Repository Staff Only: item control page